Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin
Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin
复制标题
DOI：
10.1159/000501070
复制
发表时间：
2019-01-01
影响因子：
0.8
通讯作者：
Fujita, Akira
中科院分区：
文献类型：
--
作者：
Kitazume, Koichi;Akagawa, Yuri;Fujita, Akira
外周T细胞淋巴瘤（PTCL）是一种罕见的异质性血液恶性肿瘤，涉及T或NK细胞。PTCL通常与侵袭性病程和不良预后相关。普拉曲沙（PDX）是FDA批准的第一种治疗难治性/复发性PTCL的药物。它对PTCL具有单药活性;然而，口腔粘膜炎在临床实践中代表剂量限制性毒性。我们报告的情况下，与修改THP-COP治疗（吡拉托[四氢吡喃阿霉素]，环磷酰胺和泼尼松），谁有骨或骨髓作为原发性病变，这是成功地与PDX治疗延长1年，预防性使用亚叶酸治疗口腔粘膜炎的患者。PDX的维持剂量为30 mg/m2 IV，连续给药3周，由于骨髓抑制停药1周。患者还在每次PDX给药后第2天至第6天接受亚叶酸5 mg PO，每日3次。疾病活动得到良好控制、稳定，治疗过程中未观察到口腔粘膜炎。(C)2019作者（S）由S发布。Karger AG，巴塞尔
Peripheral T-cell lymphomas (PTCLs) are a rare and heterogenous group of hematological malignancies involving T or NK cells. PTCLs are generally associated with an aggressive course and poor prognosis. Pralatrexate (PDX) is the first FDA-approved agent for the treatment of refractory/recurrent PTCL. It has single-agent activity against PTCLs; however, oral mucositis represents dose-limiting toxicity in clinical practice. We report on the case of a patient administered with modified THP-COP therapy (pirarubicin [tetrahydropyranyl adriamycin], cyclophosphamide, and prednisone), who had bone or bone marrow as the primary lesion, which was treated successfully with PDX for an extended period of 1 year, with prophylactic use of leucovorin for oral mucositis. The maintenance dose of PDX was 30 mg/m(2) IV, over 3 consecutive weeks dosing with a 1-week rest period due to bone marrow suppression. The patient also received leucovorin 5 mg PO 3 times daily from days 2 to 6 after each PDX administration. Disease activity was well controlled, stable, and no oral mucositis was observed over the course of treatment. (C) 2019 The Author(s) Published by S. Karger AG, Basel